Overcoming Challenges in Infectious Diseases
Discover the latest medical research on the prevention, management and treatment of infectious diseases.
LATEST TOPICS
-
Ceftriaxone plus levofloxacin for the treatment of Streptococcus intermedius pleuropulmonary infection11 January, 2019Ceftriaxone–levofloxacin combination is the most frequently used antimicrobial for the treatment of Streptococcus intermedius pleuropulmonary infection; drainage of pleural effusion and other... -
Sitafloxacin as part of intermittent maintenance therapy prevents recurrence of Mycobacterium avium complex lung disease5 January, 2019Intermittent maintenance therapy (IMT) that includes sitafloxacin has demonstrated positive treatment outcomes in patients treated successfully for Mycobacterium avium complex lung disease... -
Oral levofloxacin for the treatment of tracheobronchitis in a laryngectomee due to nontypeable Haemophilus influenzae26 December, 2018Oral levofloxacin was found to be effective for the treatment of beta-lactamase-producing nontypeable Haemophilus influenzae infection in a laryngectomee. A 76-year-old Caucasian man presented... -
Sitafloxacin/sulbactam combination for the treatment of extensively-drug resistant Acinetobacter baumannii infections19 December, 2018The combination of sitafloxacin and sulbactam was found to have synergistic effect and enhanced in vitro antimicrobial activity against extensively drug-resistant (XDR) Acinetobacter... -
Levofloxacin is associated with greater treatment success and lower mortality in pulmonary multidrug-resistant tuberculosis11 December, 2018An individual patient data meta-analysis showed greater treatment success and lower mortality with the use of levofloxacin – compared with other second-line drugs – for pulmonary... -
Global spread of drug-resistant superbug in hospitals5 December, 2018Researchers at the University of Melbourne uncovered three multidrug-resistant lineages of Staphylococcus epidermidis that have evolved within the hospital environment and spread globally. The... -
Levofloxacin and sitafloxacin regimens effective for Haemophilus influenzae-positive urethritis28 November, 2018Both levofloxacin and sitafloxacin regimens – recommended for the treatment of nongonococcal urethritis (NGU) in Japan – were found to be microbiologically effective for Haemophilus... -
Interview with Prof Wang Minggui21 November, 2018What are the characteristics of levofloxacin? Characteristics of levofloxacin: Pharmacodynamics: Levofloxacin is a respiratory quinolone with broad spectrum in vitro activity.... -
Levofloxacin as part of antimicrobial therapy for Mycobacterium fortuitum pulmonary infection13 November, 2018A multiple antimicrobial therapy including levofloxacin was found to be effective for Mycobacterium fortuitum pulmonary infection in a patient who did not respond to antibiotics against... -
Levofloxacin for extended-spectrum beta-lactamase- (ESBL-) producing Enterobacteriaceae infections9 November, 2018Levofloxacin is shown to be a treatment of choice for hospitalised patients with extended-spectrum beta-lactamase- (ESBL-) producing Enterobacteriaceae infections. ESBL is an enzyme that...
CONTENT LIBRARY
CONTENT LIBRARY
INTERVIEWS
-
Interview with Prof Wang Minggui -
Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia (Interview with Prof. Marin H. Kollef) -
The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (Interview with Prof. Hartmut Lode) -
Effect of Combination of Levofloxacin and Meropenem against Pseudomonas aeruginosa (Supervised by Prof. Kazuhiro Tateda, MD, PhD) -
Viewing Infectious Respiratory Disease (Supervised by Prof. Jiro Fujita, MD, PhD, ACCP) -
New Challenges for Levofloxacin in the Fight Against Infectious Diseases (Interviews with World-Renowned Experts) -
New Era for the Treatment of Respiratory Tract infections (Daiichi Pharmaceutical Co., Ltd., Special Interview) -
The Efficacy, Tolerability, and Benefits of 750 mg Once-Daily Levofloxacin in the Treatment of Community-Acquired Pneumonia (Interview with Prof. Thomas M. File, Jr, MD, MS ) -
Smarter Therapy: Guidelines for Optimal Management of Neutropenic Cancer Patients (Interview with Professor Thomas M. File, Jr.) -
Levofloxacin in the Medical Management of Community-acquired Pneumonia (Interview with Prof. Andy I. M. Hoepelman)
UPCOMING EVENTS
05 June - 09 June, 2019
Washington, DC, USA, North America
07 July - 12 July, 2019
Glasgow, United Kingdom, Western Europe
16 September - 20 September, 2019
Liverpool, UK, Western Europe
